Chinese Biotech Companies Surging with Overseas Licensing Deals
Chinese Biotech Companies Experience Growth
Chinese biotech companies are seeing a remarkable 18 percent increase in overseas licensing deals in the first quarter of the year, illustrating a strong global presence.
Key Licensing Deals
- GeneQuantum secured a significant contract worth US$13 billion with Biohaven and AimedBio to develop targeted cancer therapies.
- Harbour BioMed entered a collaboration with AstraZeneca for innovative antibodies in immunology and oncology, valued at
US$4.7 billion .
This growth persists even amid geopolitical tensions, highlighted by recent tariffs imposed by the Trump administration. Nonetheless, the Chinese healthcare industry remains resilient as essential pharmaceuticals face exemption from these tariffs. As the sector evolves, collaborations between Chinese firms and Western companies are becoming more common, emphasizing the significance of innovative drug development.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.